Loading...
Loading...
Bristol-Myers
Squibb Company
BMY and Abbott
ABT today announced results from a small, randomized Phase 2,
open-label study in patients with previously-treated multiple myeloma
that evaluated two doses of elotuzumab (10 mg/kg and 20 mg/kg) in
combination with lenalidomide and low-dose dexamethasone. In the 10
mg/kg arm, median progression-free survival (PFS), or the time without
disease progression or death, was not reached after 20.8 months of
follow up (N=36) and the objective response rate (ORR) was 92%. Of
patients who received elotuzumab at a dose of 20 mg/kg, median PFS was
18.6 months (N=37) and ORR was 76%.
The safety data are consistent with previously-reported results for
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in